Compare SSM & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSM | BIVI |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Germany | United States |
| Employees | 43 | 13 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 11.5M |
| IPO Year | N/A | 2013 |
| Metric | SSM | BIVI |
|---|---|---|
| Price | $3.93 | $1.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 93.9K | 84.6K |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,462,987.20 | N/A |
| Revenue Next Year | $48.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $0.88 |
| 52 Week High | $10.54 | $9.09 |
| Indicator | SSM | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 55.08 |
| Support Level | $3.42 | $1.45 |
| Resistance Level | $7.60 | $1.71 |
| Average True Range (ATR) | 0.85 | 0.11 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 8.55 | 52.08 |
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.